PolyPid Ltd. (PYPD)
| Market Cap | 101.25M +82.0% |
| Revenue (ttm) | n/a |
| Net Income | -31.50M |
| EPS | -1.48 |
| Shares Out | 20.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 124,423 |
| Open | 5.120 |
| Previous Close | 5.100 |
| Day's Range | 4.970 - 5.180 |
| 52-Week Range | 3.060 - 5.730 |
| Beta | 1.39 |
| Analysts | Strong Buy |
| Price Target | 11.75 (+135.71%) |
| Earnings Date | Aug 12, 2026 |
About PYPD
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral ca... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for PYPD stock is "Strong Buy." The 12-month stock price target is $11.75, which is an increase of 135.71% from the latest price.
News
PolyPid reports Q2 EPS (35c), consensus (38c)
“The second quarter of 2026 and the first few weeks of the third quarter completed PolyPid’s (PYPD) transition into a commercial-stage company, with the acceptance by the FDA with Priority…
PolyPid Earnings Call Transcript: Q2 2026
FDA accepted NDA for D-PLEX100 with priority review and no review issues, setting a PDUFA date of Nov 28, 2026. Secured a commercialization partnership with Azurity, $30M upfront, and potential for $290M+ in milestones. Cash runway extends into 2028.
PolyPid Earnings release: Q2 2026
PolyPid released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance
PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026
PETACH TIKVA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by ele...
PolyPid NDA acceptance ‘meets or exceeds’ expectations, says Roth Capital
The FDA accepted D-PLEX100’s NDA for priority review, strengthening the regulatory outlook and PolyPid’s (PYPD) balance sheet through a $15M milestone payment, with attention now turning to FDA inspec...
PolyPid announces FDA acceptance of, priority review for D-PLEX100
PolyPid (PYPD) announced that the FDA has accepted for filing the new drug application, or NDA, and granted the NDA a priority review for D-PLEX100 for the prevention of surgical…
PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀
PDUFA target action date of November 28, 2026, approximately one quarter ahead of Company's previously communicated guidance
PolyPid price target lowered to $12 from $13 at Craig-Hallum
Craig-Hallum lowered the firm’s price target on PolyPid (PYPD) to $12 from $13 and keeps a Buy rating on the shares following the company’s announcement of a commercialization partnership with…
Roth says Azurity deal validates D-PLEX100, sees limited near-term revenue
Roth Capital notes that PolyPid (PYPD) struck a $320M commercialization agreement with Azurity for potential D-PLEX100 commercialization in the U.S. and Canada. From PolyPid’s perspective, this deal p...
PolyPid Stock (PYPD) Plummets Despite Deal With Azurity to Tackle Surgical Infections
Shares in Israeli biopharmaceutical company PolyPid ($PYPD) dropped 8% in pre-market trading today despite sealing a deal with Azurity Pharmaceuticals to help millions of people around the world suffe...
PolyPid enters exclusive pact with Azurity Pharmaceuticals for D-PLEX100
PolyPid (PYPD) announced that it has entered into an exclusive commercial partnership agreement with Azurity Pharmaceuticals for the commercialization of D-PLEX100 in the United States and Canada for ...
PolyPid, Azurity sign surgical site infection drug deal
Israeli biotech PolyPid said on Tuesday it had agreed a deal with Azurity Pharmaceuticals to commercialise a drug aimed at preventing surgical site infections in the U.S. and Canada, under which it ...
PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada
PETACH TIKVA, Israel, July 21, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to elevating treatment effectiveness...
PolyPid completes NDA submission to FDA for D-PLEX100
PolyPid (PYPD) announced the completion of its new drug application, or NDA, submission on a rolling review basis to the FDA for D-PLEX100, the company’s lead product candidate for the…
PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀
If approved, D-PLEX100 would address a critical unmet medical need in the prevention of surgical site infections
PolyPid Transcript: Lytham Partners Spring 2026 Investor Conference
D-PLEX100 is advancing through regulatory milestones, with FDA and EU approvals targeted for 2027. Phase III data show significant reductions in infection rates and severity, and strong market interest is supported by cost-saving incentives and NTAP eligibility.
PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference
PETACH TIKVA, Israel, May 20, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elev...
PolyPid reports Q1 EPS (35c), consensus (43c)
“The first quarter of 2026 marked an important transition for PolyPid (PYPD), as we moved from late-stage development to the final stage prior to drug approval, the regulatory review stage,…
PolyPid Earnings Call Transcript: Q1 2026
Transitioned to final NDA submission for D-PLEX100, with U.S. partnership talks in late stages and European MAA submission planned for Q3 2026. Q1 net loss improved year-over-year, cash position strengthened by loan repayment, and clinical data supports product efficacy.
PolyPid Earnings release: Q1 2026
PolyPid released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results
Initiated NDA Submission to the FDA for D-PLEX₁₀₀ ; Completion Expected Imminently U.S. Commercial Partnership Discussions in Late Stages Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKV...
PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026
PETACH TIKVA, Israel, May 06, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elev...
PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting
Analysis demonstrates statistically significant reduction in the severity of surgical wound infections, with potential to lower hospital resource utilization following abdominal colorectal surgery PET...
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026
Analysis demonstrates D-PLEX₁₀₀ prolonged delivery mechanism ability to deliver continuous release of doxycycline for 30 days at the surgical incision site Analysis demonstrates D-PLEX₁₀₀ prolonged de...